Valesca Anschau

Prognosys Biosciences (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Luís Eduardo Soares Netto

Universidade de São Paulo

Alexandre Rosa Campos

Discovery Institute

Renata Bannitz Fernandes

Universidade de São Paulo

Issa Isaac

Biognosys (Switzerland)

Marcos Antônio de Oliveira

Universidade Estadual Paulista (Unesp)

Todd Hembrough

Triangle

Alan M. Ezrin

University of Miami

Cheryl Bandoski

University of New Haven

Martin Mehnert

Biognosys (Switzerland)

Poorva Mudgal

Wake Forest University

Cooperative Institutions

Universidade de São Paulo

Discovery Institute

Sanford Burnham Prebys Medical Discovery Institute

Torrey Pines Institute For Molecular Studies

Epigenomics (Germany)

La Jolla Alcohol Research

Sanford Research

University of Pennsylvania

Instituto Butantan

Universidade Estadual Paulista (Unesp)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer

Prostate Cancer (2013)

Henrique B. da Silva Eduardo P. Amaral Eduardo Lima Nolasco Nathália Cruz de Victo Rodrigo Atique

Prostate cancer (PCa) is one of the most common malignancies found in males. The development of PCa involves several mutations in prostate epithelial cells, usually linked to developmental changes, such as enhanced resistance to apoptotic death, constitutive proliferation, and, in some cases, to differentiation into an androgen deprivation-resistant phenotype, leading to the appearance of castration-resistant PCa (CRPCa), which leads to a poor prognosis in patients. In this review, we summarize recent findings concerning the main deregulations into signaling pathways that will lead to the development of PCa and/or CRPCa. Key mutations in some pathway molecules are often linked to a higher prevalence of PCa, by directly affecting the respective cascade and, in some cases, by deregulating a cross-talk node or junction along the pathways. We also discuss the possible environmental and nonenvironmental inducers for these mutations, as well as the potential therapeutic strategies targeting these signaling pathways. A better understanding of how some risk factors induce deregulation of these signaling pathways, as well as how these deregulated pathways affect the development of PCa and CRPCa, will further help in the development of new treatments and prevention strategies for this disease.

10.1155/2013/920612

Cite

Citations (65)

Fish oil protects rat erythrocytes against oxidative stress caused by Trypanosoma evansi infection

Comparative Clinical Pathology (2017)

Valesca Anschau Maiara Anschau Floriani Mayara Vieira Tizatto Luiz Cláudio Miletti

Trypanosoma evansi

Glutathione reductase

10.1007/s00580-017-2433-3

Cite

Citations (2)

Abstract A063: Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers

Clinical Cancer Research (2024)

Poorva Mudgal Cheryl Bandoski Zachary Opheim Martin Mehnert Valesca Anschau

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR013) of the Conference Program/Proceedings. Citation Format: Poorva Mudgal, Cheryl Bandoski, Zachary Opheim, Martin Mehnert, Valesca Anschau, Issa Isaac, Alan Ezrin, Todd Hembrough. Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers [abstract]. In: Proceedings of the AACR Special Conference: Liquid Biopsy: From Discovery to Clinical Implementation; 2024 Nov 13-16; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(21_Suppl):Abstract nr A063.

Extracellular Vesicles

Cancer Biomarkers

10.1158/1557-3265.liqbiop24-a063

Cite

Citations (0)

A BioID-derived proximity interactome for SARS-CoV-2 proteins

bioRxiv (Cold Spring Harbor Laboratory) (2021)

Danielle G. May Laura Martin‐Sancho Valesca Anschau Sophie Liu Rachel J. Chrisopulos

Abstract The novel coronavirus SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic and has caused a major health and economic burden worldwide. Understanding how SARS-CoV-2 viral proteins behave in host cells can reveal underlying mechanisms of pathogenesis and assist in development of antiviral therapies. Here we use BioID to map the SARS-CoV-2 virus-host interactome using human lung cancer derived A549 cells expressing individual SARS-CoV-2 viral proteins. Functional enrichment analyses revealed previously reported and unreported cellular pathways that are in association with SARS-CoV-2 proteins. We have also established a website to host the proteomic data to allow for public access and continued analysis of host-viral protein associations and whole-cell proteomes of cells expressing the viral-BioID fusion proteins. Collectively, these studies provide a valuable resource to potentially uncover novel SARS-CoV-2 biology and inform development of antivirals.

Interactome

Proteome

Coronavirus

10.1101/2021.09.17.460814

Cite

Citations (5)

Identification and characterization of reduction agents of 1-Cys peroxiredoxins from Aspergillus fumigatus , a human opportunistic pathogen

Free Radical Biology and Medicine (2018)

Renata Bannitz Fernandes Krissia Franco de Godoy Iran Malavazi Valesca Anschau Adriano B. Chaves‐Filho

Peroxiredoxin

Human pathogen

10.1016/j.freeradbiomed.2018.04.513

Cite

Citations (3)

Kinetic Characterization of Sulfenic Acid Reduction in 1-Cys Peroxiredoxins by Ascorbate

Free Radical Biology and Medicine (2014)

Valesca Anschau Gerardo Ferrer‐Sueta Stephanie Portillo‐Ledesma Luís Eduardo Soares Netto

Sulfenic acid

10.1016/j.freeradbiomed.2014.10.106

Cite

Citations (1)

A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins

Viruses (2022)

Danielle G. May Laura Martin‐Sancho Valesca Anschau Sophie Liu Rachel J. Chrisopulos

The novel coronavirus SARS-CoV-2 is responsible for the ongoing COVID-19 pandemic and has caused a major health and economic burden worldwide. Understanding how SARS-CoV-2 viral proteins behave in host cells can reveal underlying mechanisms of pathogenesis and assist in development of antiviral therapies. Here, the cellular impact of expressing SARS-CoV-2 viral proteins was studied by global proteomic analysis, and proximity biotinylation (BioID) was used to map the SARS-CoV-2 virus-host interactome in human lung cancer-derived cells. Functional enrichment analyses revealed previously reported and unreported cellular pathways that are associated with SARS-CoV-2 proteins. We have established a website to host the proteomic data to allow for public access and continued analysis of host-viral protein associations and whole-cell proteomes of cells expressing the viral-BioID fusion proteins. Furthermore, we identified 66 high-confidence interactions by comparing this study with previous reports, providing a strong foundation for future follow-up studies. Finally, we cross-referenced candidate interactors with the CLUE drug library to identify potential therapeutics for drug-repurposing efforts. Collectively, these studies provide a valuable resource to uncover novel SARS-CoV-2 biology and inform development of antivirals.

Interactome

2019-20 coronavirus outbreak

Sars virus

10.3390/v14030611

Cite

Citations (41)

Glutathione and iron at the crossroad of redox metabolism in rats infected by Trypanosoma evansi

Parasitology Research (2013)

Valesca Anschau Alcir Luiz Dafré Ana Paula A. Perin Fabíola Iagher Mayara Vieira Tizatto

Erythrocyte fragility

Mean corpuscular hemoglobin

Trypanosoma evansi

10.1007/s00436-013-3400-9

Cite

Citations (7)

Histone chaperone HIRA, promyelocytic leukemia protein, and p62/SQSTM1 coordinate to regulate inflammation during cell senescence

Molecular Cell (2024)

Nirmalya Dasgupta Xue Lei Christina Huan Shi Rouven Arnold Marcos G. Teneche

Promyelocytic leukemia protein

Senescence

Chaperone (clinical)

10.1016/j.molcel.2024.08.006

Cite

Citations (4)

Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers.

Journal of Clinical Oncology (2025)

Todd Hembrough Poorva Mudgal Zachary Opheim Cheryl Bandoski Issa Isaac

262 Background: Colorectal cancer (CRC) is one of the most common cancers worldwide, and early detection is critical for successful treatment and improved survival rates. However, precancerous and early-stage CRC present significant diagnostic challenges due to the small size of lesions and the very low expression of tumor-specific biomarkers in the bloodstream. Current genomics-based diagnostic methods struggle to detect these early-stage and precancerous lesions, making it imperative to develop more sensitive and specific approaches. Circulating extracellular vesicles (EVs) are emerging as a promising solution for early-stage CRC detection. Since EVs are produced by tumor cells as well as tumor microenvironment and host immune response cells, EVs offer the means to detect and monitor small early-stage tumors through both direct detection of tumor-associated biomarkers as well as tumor specific host response and tumor microenvironment biomarkers. Methods: To identify novel early-stage CRC specific biomarkers, we performed proteomics analysis on EVs purified from patient plasma using size exclusion chromatography and a proprietary buffer system that enhances EV and corona protein recovery. TrueDiscovery Data-independent acquisition (DIA) mass spectrometry (MS) analysis was conducted on 24 pre-cancer/stage 0 and 25 stage 1 CRC patients and 75 normal patient plasma samples. An in-house developed machine learning pipeline was used to identify differentially expressed proteins and model candidate multiplexes to identify those with extremely high diagnostic accuracy (> 0.99). Results: An average of ~2,500 proteins were identified per sample and included in bioinformatics analysis. Comparative analysis between control patient EVs and either pre-cancerous/Stage 0, or Stage 1 colon cancer EVs using an in-house Machine Learning pipeline identified 336 and 493 differentially expressed proteins for each group (FDR adjusted p-value < 0.001). Of these, the best 17 pre/stage 0 proteins and 53 stage 1 proteins were trained and tested using Support Vector Machine to assess all potential 3-plexes in order to identify those with mean diagnostic accuracy > 99%. This yielded 5 3-plexes in precancer/stage 0 and 34 3-plexes in stage 1 with near perfect diagnostic accuracy. These plexes are currently being assessed in single analyte and multiplex immunoassays with the goal of translating candidate 3-plexes to the clinical. Conclusions: Key biomarkers from CRC patient EVs indicate the potential to detect and diagnose early-stage and low tumor burden cancers using our methods. Interestingly, the most accurate 3-plexes consist of proteins from immune, inflammatory and metabolic processes, suggesting that for the detection of early stage cancer it may be critical to include both tumor and host specific biomarkers.

Extracellular Vesicles

10.1200/jco.2025.43.4_suppl.262

Cite

Citations (0)